HEP-1 (Gepon)

HEP-1 (Human Ezrin Peptide 1), known clinically in Russia as Gepon, is a synthetic 14-amino-acid peptide derived from amino acids 324-337 of the human ezrin protein. Ezrin is a cytoskeletal protein that links membrane proteins to the actin cytoskeleton and plays roles in immune-cell signaling, viral assembly, and bacterial pathogen interactions. The HEP-1 fragment was identified as a bioactive immunomodulatory peptide with effects on macrophage activation, cytokine balance, and mucosal immunity.

Gepon was developed in Russia by Andrey Ataullakhanov and colleagues and was approved by Russian regulatory authorities in the early 2000s for use as an adjunct therapy in HIV/AIDS, viral hepatitis, recurrent herpes infections, and other conditions involving impaired mucosal immunity. The compound is administered via multiple routes including oral, intranasal, topical, and rectal, with the route selected based on the target compartment of immune activation. Gepon has been used clinically in Russia for over two decades with a generally favorable safety profile.

Western clinical literature on HEP-1 is essentially absent. The Russian clinical evidence base is real but has not been independently replicated in Western settings, and the compound's mechanism of action is less well characterized at the molecular level than the more recently developed immunomodulatory peptides. Research-chemical vendors sell HEP-1 under both names.

Gepon was developed in Russia in the late 1990s and approved by the Russian regulatory authority (Roszdravnadzor) in the early 2000s for use as an immunomodulator in viral and bacterial infections, particularly HIV/AIDS, chronic hepatitis, and recurrent herpes simplex. The compound is produced and marketed by the Russian pharmaceutical company Immapharma. Clinical use has expanded over two decades through Russian medical practice but has not been adopted in Western medicine.